|
Blood Lipidomic And Breast Cancer Risk: Protocol of A Systematic Review
|
Zahra Hosseinpour    , Mahsa Alem , Elham Anari , Razieh Anari * |
| Nutrition and Metabolic Diseases Research Center, Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61375-15794, Iran , Raziehanari85@yahoo.com |
|
|
Abstract: (512 Views) |
Background and objectives: Breast cancer is the most common type of cancer and the leading cause of death in women worldwide. Early detection of breast cancer by measuring metabolites that can be easily detected through blood tests will significantly help in time treatment, prevent cancer progression, and reduce the risk of death in breast cancer patients. One of the constant metabolic characteristics of cancer is lipidomic remodeling, which includes changes in fatty acid transport, lipogenesis, lipid storage, and beta-oxidation to supply energy. This review aims to compare lipid changes between women with and without breast cancer.
Materials and methods: The systematic review will search and summarize data on observational studies from Medline/PubMed, Scopus, Embase, and Web of Science databases and grey literature published between January 2000 and January 2025. Keywords related to 'breast cancer' and 'lipidomic' will be used to retrieve relevant documents. The PECOS model will be used to include eligible studies. The protocol of this systematic review follows the PRISMA-P statement.
Results and conclusion: This systematic review will help summarize the existing evidence about the use of blood lipids in breast cancer diagnosis and prognosis and recognize the current gaps in research to design further high-quality studies with the ultimate goal of easy and early detection of breast cancer. |
|
| Keywords: Blood lipids, Breast cancer, Lipidomic, Protocol, Systematic review |
|
|
Full-Text [PDF 545 kb]
(162 Downloads)
|
Article type: Study Protocol |
Subject:
Nutrition
Received: 2025/02/10 | Accepted: 2025/04/7 | Published: 2025/04/30
|
|
|
|
- Early detection of breast cancer by measuring metabolites through blood tests will help in time treatment, prevent cancer progression
- This systematic review will search and summarize observational studies on blood lipids and breast cancer
- The PECOS model will be used to include eligible studies
- Keywords related to breast cancer and lipidomic will be used
|
|
| References |
1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022;66:15-23. [ DOI:10.1016/j.breast.2022.08.010] 2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646-74. [ DOI:10.1016/j.cell.2011.02.013] 3. Strickaert A, Saiselet M, Dom G, De Deken X, Dumont JE, Feron O, et al. Cancer heterogeneity is not compatible with one unique cancer cell metabolic map. Oncogene. 2017;36(19):2637-42. [ DOI:10.1038/onc.2016.411] 4. Jin H-R, Wang J, Wang Z-J, Xi M-J, Xia B-H, Deng K, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. Journal of Hematology & Oncology. 2023;16(1):103. [ DOI:10.1186/s13045-023-01498-2] 5. Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021;10(5):1056. [ DOI:10.3390/cells10051056] 6. Monaco ME. Fatty acid metabolism in breast cancer subtypes. Oncotarget. 2017;8(17):29487. [ DOI:10.18632/oncotarget.15494] 7. Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer cell. 2016;30(5):668-81. [ DOI:10.1016/j.ccell.2016.09.011] 8. Wang H, Franco F, Tsui Y-C, Xie X, Trefny MP, Zappasodi R, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature immunology. 2020;21(3):298-308. [ DOI:10.1038/s41590-019-0589-5] 9. Fichtali K, Bititi A, Elghanmi A, Ghazi B. Serum lipidomic profiling in breast cancer to identify screening, diagnostic, and prognostic biomarkers. BioResearch Open Access. 2020;9(1):1-6. [ DOI:10.1089/biores.2018.0022] 10. Ni H, Liu H, Gao R. Serum lipids and breast cancer risk: a meta-analysis of prospective cohort studies. PloS one. 2015;10(11):e0142669. [ DOI:10.1371/journal.pone.0142669] 11. Wu J, Lei X, Pan X, Zeng X, Li W. Association between serum lipids and breast cancer risk in premenopausal women: systematic review and meta-analysis. Journal of International Medical Research. 2021;49(11):03000605211061033. [ DOI:10.1177/03000605211061033] 12. Nouri M, Mohsenpour MA, Katsiki N, Ghobadi S, Jafari A, Faghih S, et al. Effect of serum lipid profile on the risk of breast cancer: systematic review and meta-analysis of 1,628,871 women. Journal of clinical medicine. 2022;11(15):4503. [ DOI:10.3390/jcm11154503] 13. Touvier M, Fassier P, His M, Norat T, Chan DS, Blacher J, et al. Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. British Journal of Nutrition. 2015;114(3):347-57. [ DOI:10.1017/S000711451500183X] 14. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4:1-9. [ DOI:10.1186/2046-4053-4-1] 15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021;372. [ DOI:10.1136/bmj.n71] 16. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25:603-5. [ DOI:10.1007/s10654-010-9491-z] 17. Reeves BC, Deeks JJ, Higgins JP, Wells GA. Including non‐randomized studies. Cochrane handbook for systematic reviews of interventions: Cochrane book series. 2008:389-432. [ DOI:10.1002/9780470712184.ch13] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
|
